FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment

The US Food and Drug Administration (FDA) has imposed a clinical hold on Kezar Life Sciences’ investigational new drug application for zetomipzomib, aimed at treating LN.

This decision is in direct response to the company’s voluntary suspension of subject enrolment and dosing in the Phase II PALIZADE clinical trial.